Oncternal Therapeutics, Inc. (ONCT)

USD 0.53

(-24.12%)

Market Cap (In USD)

1.55 Million

Revenue (In USD)

785 Thousand

Net Income (In USD)

-39.47 Million

Avg. Volume

62.26 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.5266-13.14
PE
-0.045
EPS
-11.69
Beta Value
1.358
ISIN
US68236P2065
CUSIP
68236P107
CIK
1260990
Shares
2959640.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. James B. Breitmeyer M.D., Ph.D.
Employee Count
-
Website
https://www.oncternal.com
Ipo Date
2004-02-03
Details
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.